Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion
1.7.2026 12:01:00 CEST | Business Wire | Press Release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/
Dr. Hubert Scholze, Chief Business Officer, Rezon Bio
As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution.
His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated biologics CDMO offering, expanding its global commercial footprint while investing in the capabilities, expertise and partnerships needed to support biosimilars and novel biologics programs from early development to commercial manufacturing.
Dr. Hubert Scholze brings more than 25 years of experience spanning biologics manufacturing, operations and global business development across the pharmaceutical and CDMO industries. Prior to joining Rezon Bio, he led Global Business Development for Catalent’s Core Biologics division, overseeing commercial activities for integrated mammalian drug substance and sterile drug product development and manufacturing services.
“Hubert brings a unique combination of manufacturing expertise, commercial leadership and a deep understanding of the biologics industry and client needs,” said Dr. Adriana Kiędzierska-Mencfeld, Chief Executive Officer (CEO) of Rezon Bio. “His leadership will strengthen how we integrate commercial strategy, scientific excellence and operational execution to deliver greater value for our clients as our organization enters the next phase of growth.”
“I am excited to join Rezon Bio at such an important moment in the company’s journey,” said Dr. Scholze. “What attracted me the most is the proven track record, strong scientific and manufacturing expertise, and talented people who are passionate about delivering for their clients. Combined with a clear ambition for international growth, this creates a strong foundation for the future. I look forward to working with our teams and clients to build long-term partnerships, expand our global presence, and help bring innovative biologic therapies to patients worldwide.”
Dr. Scholze began his career at Boehringer Ingelheim in Vienna, where he held leadership positions in biologics manufacturing, including Unit Head of a large-scale microbial fermentation facility and Manufacturing Director. After several years in manufacturing, he transitioned into sales and business development, taking on roles of increasing responsibility at leading pharmaceutical and biologics CDMO organizations, including Aenova Group and Catalent. Throughout his career, he has partnered with emerging biotech companies and global pharmaceutical organizations, supporting programs from early-phase development through large-scale commercial manufacturing.
Hubert Scholze, PhD, holds a doctorate in Biochemistry from University of Technology Graz, Austria.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
For more information, please visit: https://rezonbio.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260701630118/en/
Contacts
Media Contact:
Loukiani Chatzinasiou
loukiani.chatzinasiou@rezonbio.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SamanTree Medical’s Histolog ® Scanner Technology Featured in 13 Publications in Special BJU International Issue on Confocal Microscopy in Urology1.7.2026 15:01:00 CEST | Press Release
SamanTree Medical, a global leader in surgical imaging innovation, today announced that Histolog Scanner confocal microscopy technology has been featured in 13 peer-reviewed clinical papers in a special issue of BJU International, one of the world’s leading journals in urology. The special edition focuses on a growing body of evidence of the role of confocal microscopy in urologic surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701425845/en/ SamanTree Medical announces that Histolog® Scanner confocal microscopy technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International. “The special issue represents increasing momentum behind confocal microscopy in urologic surgery,” said Professor Greg Shaw, consultant urologic surgeon at University College London Hospitals (UCLH) and author of several studies in the special issue. “This collection, ranging from radical prostatectomy to eme
Regnology to Acquire Fed Reporter, Accelerating U.S. Leadership and Advancing Regulatory Modernization1.7.2026 15:00:00 CEST | Press Release
Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced it has entered into a definitive agreement to acquire Fed Reporter, the market-leading U.S. provider of regulatory reporting solutions for financial institutions of all sizes, including banks, credit unions, and bank holding companies. The acquisition marks a pivotal milestone in Regnology’s U.S. expansion, creating the most comprehensive regulatory reporting coverage across the American financial landscape and extending its reach to more than 4,000 institutions from global banks to community lenders. By combining a proven, cloud-first, agentic-first technology foundation with deeply embedded local expertise, Regnology is uniquely positioned to support more efficient, transparent, and data-driven reporting, while strengthening alignment between financial institutions and supervisory authorities. “This is the next step in our U.S. strategy,” said Rob Mackay, CEO of Regnolog
Xsolla Announces Scholarship Program to Support Emerging Developers1.7.2026 15:00:00 CEST | Press Release
Xsolla, a leading global video game commerce company, today announced the launch of the Xsolla Developer Scholarship Program - Cologne 2026 an initiative designed to support independent and mid-tier game developers who face financial barriers to attending gamescom 2026 in Cologne, Germany. As the world’s largest gaming event, gamescom brings together developers, publishers, investors, and industry leaders from across the globe to explore new opportunities, showcase innovative projects, and build meaningful business relationships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701200418/en/ Graphic: Xsolla The developer scholarship program is designed to help promising studios and independent creators gain access to one of the industry’s most influential events by providing professional development and networking opportunities to accelerate their growth and success. Building on Xsolla’s commitment to supporting game creato
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i ® Program1.7.2026 13:55:00 CEST | Press Release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule API and HPAPI, announced today that AGC has successfully completed an onsite assessment of its new Barcelona facility using the VERIF.i® supplier pre-assessment program. The newly expanded Barcelona site strengthens AGC’s position as a global leader in the development and commercialization of complex small molecule Active Pharmaceutical Ingredients (APIs) and highly potent APIs (HPAPIs). Designed for maximum flexibility, safety, and energy efficiency, the facility expands AGC’s end-to-end capabilities from gram-scale to ton-scale production under the highest quality and sustainability standards. “At AGC Pharma Chemicals, we place the highest priority on the integrity of our operational processes and the expertise of our frontline teams,” said Jun Kurihar
Introducing Arbex: a New Global Leader in Tissue and Hygiene1.7.2026 13:37:00 CEST | Press Release
Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture between Suzano (NYSE: SUZ), the world’s largest pulp supplier, and Kimberly-Clark Corporation (NASDAQ: KMB), a global leader in consumer goods and personal care, the new business will manufacture, market and distribute consumer and professional products across more than 70 markets on five continents. Arbex has assumed ownership of assets previously run by Kimberly-Clark’s International Family Care & Professional (IFP) business unit, which includes 22 manufacturing sites in 14 countries, and a portfolio of more than 40 regional brands including Andrex®, Hakle®, and Scottex®. The company also holds a long-term license for the use of Kimberly-Clark’s global brands, including Kleenex®, Cottonelle®, Scott®, WypAll®, Viva®, and Kimberly-Clark Professional. Ehab A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom